CDP-840 hydrochloride

CAS No.

CDP-840 hydrochloride ( CDP840;L-765527 )

Catalog No. M16967 CAS No.

CDP-840 (CDP840;L-765527) is a potent and selective PDE4 inhibitor with IC50 of 4-45 nM.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    CDP-840 hydrochloride
  • Note
    Research use only, not for human use.
  • Brief Description
    CDP-840 (CDP840;L-765527) is a potent and selective PDE4 inhibitor with IC50 of 4-45 nM.
  • Description
    CDP-840 (CDP840;L-765527) is a potent and selective PDE4 inhibitor with IC50 of 4-45 nM for PDE 4 extracted from tissues or recombinant PDE 4 isoforms expressed in yeast; shows no effect for PDE-1, 2, 3, 5, and 7 (IC50>100 uM), exhibits no significant selectivity in inhibiting human recombinant isoenzymes PDE-4A, B, C or D and is equally active against the isoenzymes lacking UCR1 (PDE-4B2 and PDE-4D2); causes a dose-dependent reduction of IL-5-induced pleural eosinophilia in rats (ED50=0.03 mg/kg); prevents antigen-induced eosinophilia and bronchoconstriction; orally active.Asthma Phase 2 Discontinued
  • Synonyms
    CDP840;L-765527
  • Pathway
    Angiogenesis
  • Target
    PDE
  • Recptor
    PDE
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    --
  • Formula Weight
    409.95
  • Molecular Formula
    C25H27NO2.HCl
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    4-[(2R)-2-[3-(Cyclopentyloxy)-4-methoxyphenyl]-2-phenylethyl]-pyridine hydrochloride

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Hughes B, et al. Br J Pharmacol. 1996 Jul;118(5):1183-91.
2. Holbrook M, et al. Br J Pharmacol. 1996 Jul;118(5):1192-200.
3. Perry MJ, et al. Cell Biochem Biophys. 1998;29(1-2):113-32.
molnova catalog
related products
  • GSK 356278

    A potent, selective, brain-penetrant and orally bioavailable phosphodiesterase 4 (PDE4) inhibitor with pIC50 of 8.8 (PDE4B); equally inhibits PDE4A and PDE4Dwith pIC50 of 8.6 and 8.7.

  • Zomepirac Sodium

    Zomepirac, formerly marketed as Zomax tablets, was associated with fatal and near-fatal anaphylactoid reactions.

  • Tofimilast

    Tofimilast (CP-325366) is a potent, selective PDE4 inhibitor with IC50 of 23, 13 and 13 nM for PDE4A, PDE4B, and PDE4D, respectively.